TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10536064

Group type: EXPERIMENTAL
Intervention: Once-daily administration of budesonide (200-400 microg/day)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Twice-daily administration of budesonide (200-400 microg/day)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Comparison of both treatments
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Secondary efficacy measures
Number of subjects: 206
Study: 7477799

Group type: EXPERIMENTAL
Intervention: 5-minute EEG recording under vigilance-controlled condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-minute EEG recording under resting condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer EEG recording duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-minute EEG recording
Number of subjects: 0
Study: 2203254

Group type: EXPERIMENTAL
Intervention: Higher-protein diet (1.0 g protein.kg body wt‐1.d‐1)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Lower-protein diet (0.6 g protein.kg body wt‐1.d‐1)
Number of subjects: 2
Study: 6992927

Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31372871

Group type: EXPERIMENTAL
Intervention: Behavioral reproductive research study participation
Number of subjects: 44
Study: 29507752

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CTD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study: 27028008

Group type: EXPERIMENTAL
Intervention: Plan recommendations (social normative, physician, government)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Government or providers recommending the lowest cost plan
Number of subjects: 656

Group type: COMPARATOR
Intervention: Control condition (no recommendations)
Number of subjects: 656
Study: 25194963

Group type: EXPERIMENTAL
Intervention: Meal Replacement (MR) - low-calorie, high soy-protein drink with a low glycemic index
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lifestyle Intervention (LS) - dietary counseling sessions and increased physical activity
Number of subjects: 42
Study: 22348981

Group type: EXPERIMENTAL
Intervention: Coated implants with a thin fibrinogen layer containing 2 bisphosphonates
Number of subjects: 16

Group type: COMPARATOR
Intervention: Untreated implants
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coated implants
Number of subjects: 16
Study: 20228219

Group type: EXPERIMENTAL
Intervention: Compound herbal preparation (CHP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120
Study: 18265662

Group type: EXPERIMENTAL
Intervention: Standard interferon-alpha (9/10 MU) three times a week plus lamivudine 100mg daily for 52 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lamivudine monotherapy after combination therapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Standard interferon-alpha plus lamivudine
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Long-term antiviral maintenance therapy
Number of subjects: 37
Study: 14872247

Group type: EXPERIMENTAL
Intervention: Tea condition (hot brewed tea as a major part of fluid intake)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No tea condition (tea excluded from the diet)
Number of subjects: 13
Study: 11196521

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) 1 g/day
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 9853436

Group type: EXPERIMENTAL
Intervention: Early elective open surgery (n=563)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Ultrasonographic surveillance (n=527)
Number of subjects: 1090
Study: 7916401

Group type: EXPERIMENTAL
Intervention: Phosphoramidon (inhibitor of endothelin converting enzyme)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BQ-123 (selective endothelin receptor A antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proendothelin-1 (precursor to endothelin-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endothelin-1
Number of subjects: 0
Study: 2816360

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment for 6 months
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1215880

Group type: EXPERIMENTAL
Intervention: 3 X 5000 IU s. c. heparin daily (starting preoperatively)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Heparin in males
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Heparin in females
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Heparin in patients under 60 years
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Heparin in obese patients
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Heparin in patients with predisposing factors
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Heparin side effects
Number of subjects: 178
Study: 31390762

Group type: EXPERIMENTAL
Intervention: Combined synbiotics and BCAAs treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 28472667

Group type: EXPERIMENTAL
Intervention: C‐LED (blue-depleted circadian-sensitive light)
Number of subjects: 16

Group type: COMPARATOR
Intervention: FL (standard fluorescent light)
Number of subjects: 16
Study: 25600221

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 ppb ozone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 ppb ozone
Number of subjects: 24
Study: 23507791

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide (high-dose group, n = 20)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone acetonide (low-dose group, n = 20)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 53
Study: 21499192

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab (1.25 mg) 1 week before vitrectomy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 35
Study: 19335800

Group type: EXPERIMENTAL
Intervention: 10 mg lidocaine hydrochloride 10% spray
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 20 mg lidocaine hydrochloride 10% spray
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 17037894

Group type: EXPERIMENTAL
Intervention: Root ZX
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Foramatron D10
Number of subjects: 36

Group type: COMPARATOR
Intervention: Apex NRG
Number of subjects: 36

Group type: COMPARATOR
Intervention: Apit 7
Number of subjects: 36
Study: 15213896

Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in BA patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in BA patients with poor outcome
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in BA patients with fair outcome
Number of subjects: 28

Group type: COMPARATOR
Intervention: Serum hepatocyte growth factor (HGF) in controls
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in group A (good outcome)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in group B (fair outcome)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Serum hepatocyte growth factor (HGF) in group C (poor outcome)
Number of subjects: 28
Study: 16677162

Group type: EXPERIMENTAL
Intervention: Ulcerative colitis patients (active disease)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ulcerative colitis patients (remission)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ulcerative colitis patients (≥4 recurrences)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 10230943

Group type: EXPERIMENTAL
Intervention: Early extubation (mean delay, 3.49±2.21 hours)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Late extubation (mean delay, 10.32±1.75 hours)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (early and late extubation)
Number of subjects: 48
Study: 9091555

Group type: EXPERIMENTAL
Intervention: TUIP alone
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: TUIP + LHRH analogue
Number of subjects: 74
Study: 1914480

Group type: EXPERIMENTAL
Intervention: Selective parenteral and enteral antisepsis regimen (oral nonabsorbable antimicrobial agents: polymyxin E, gentamicin, and amphotericin B; parenteral cefotaxime)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Perioperative antibiotic prophylaxis or antibiotic therapy according to clinical or microbiological evidence of infection
Number of subjects: 50
Study: 7037661

Group type: EXPERIMENTAL
Intervention: Flutonidin (2-4 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol (20-40 mg daily)
Number of subjects: 0
Study: 31981227

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 76
Study: 30782917

Group type: EXPERIMENTAL
Intervention: Telephone-delivered dietary intervention with a mail-delivered workbook and scheduled phone calls from a dietitian over 4 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 140
Study: 28118856

Group type: EXPERIMENTAL
Intervention: NIRS-based neurofeedback training in VR
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: NIRS-based neurofeedback training in 2D
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Electromyogram-based biofeedback training in VR
Number of subjects: 90
Study: 27026145

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 370
Study: 24903197

Group type: EXPERIMENTAL
Intervention: Hemostatic sealant (FloSeal™)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bipolar coagulation
Number of subjects: 100
Study: 22894887

Group type: EXPERIMENTAL
Intervention: Intercessory prayer
Number of subjects: 999
Study: 19649577

Group type: COMPARATOR
Intervention: Conventional anchorage (transpalatal arch)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Skeletal anchorage via mini-implants in the anterior palate
Number of subjects: 20
Study: 17301557

Group type: EXPERIMENTAL
Intervention: TMC114/r 400/100 mg once daily
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: TMC114/r 800/100 mg once daily
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: TMC114/r 400/100 mg twice daily
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: TMC114/r 600/100 mg twice daily
Number of subjects: 318

Group type: COMPARATOR
Intervention: CPI(s)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: TMC114/r
Number of subjects: 318
Study: 15135548

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control procedure (placebo)
Number of subjects: 7
Study: 11588459

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with six aliquots of 20-mL sterile normal saline at 37 degrees C infused through the bronchoscope.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control groups (not specified in detail).
Number of subjects: 27
Study: 9887897

Group type: EXPERIMENTAL
Intervention: Buteyko breathing techniques (BBT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 7880228

Group type: EXPERIMENTAL
Intervention: Atovaquone (750 mg orally with meals three times daily for 21 days)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Pentamidine (3 to 4 mg per kg body weight intravenously once daily for 21 days)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Atovaquone
Number of subjects: 109

Group type: COMPARATOR
Intervention: Pentamidine
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Atovaquone and Pentamidine
Number of subjects: 109
Study: 31834064

Group type: EXPERIMENTAL
Intervention: RTP group (received sports return‐to‐play guideline information)
Number of subjects: 828

Group type: COMPARATOR
Intervention: No-RTP group (did not receive sports return‐to‐play guideline information)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: RTP group
Number of subjects: 828

Group type: COMPARATOR
Intervention: No-RTP group
Number of subjects: 828
Study: 30993344

Group type: EXPERIMENTAL
Intervention: 7.5% fermented feed
Number of subjects: 720

Group type: COMPARATOR
Intervention: 0.0% fermented feed (control)
Number of subjects: 720
Study: 28335877

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Psychodynamic Therapy (PDT)
Number of subjects: 81
Study: 26508386

Group type: EXPERIMENTAL
Intervention: CoreValve TAVR
Number of subjects: 634
Study: 23261707

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure in multiple contexts
Number of subjects: 30

Group type: COMPARATOR
Intervention: Virtual reality exposure in single context
Number of subjects: 30
Study: 22117602

Group type: EXPERIMENTAL
Intervention: Multi-faceted quality improvement intervention (training of health workers, facilitation, supervision, face-to-face feedback)
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Partial intervention (didactic training and written feedback only)
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Multi-faceted quality improvement intervention
Number of subjects: 1160
Study: 18700212

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 3069

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 3069

Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors
Number of subjects: 3069

Group type: EXPERIMENTAL
Intervention: Other antidepressants
Number of subjects: 3069

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 3069
Study: 17086007

Group type: EXPERIMENTAL
Intervention: Medical devices for chronic disease management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmaceutical agents for chronic disease management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COX-2 anti-inflammatory drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implantable devices requiring catheter-based surgical procedures
Number of subjects: 0
Study: 14534587

Group type: EXPERIMENTAL
Intervention: Waking reactivation of previously consolidated memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep stages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor skill finger-tapping task
Number of subjects: 0
Study: 11061574

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg per day for 9 days)
Number of subjects: 8
Study: 9352161

Group type: EXPERIMENTAL
Intervention: Dicea cellulose membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cellulose diacetate membrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low flux polysulfone membrane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All membranes
Number of subjects: 0
Study: 8460612

Group type: EXPERIMENTAL
Intervention: Diet containing 21.9 mumol Zn/d (I)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Diet containing 37.5 mumol Zn/d (II)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Diet containing 51.6 mumol Zn/d (III)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Diet containing 67.8 mumol Zn/d (IV)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Diet containing 159 mumol Zn/d (X)
Number of subjects: 11
Study: 3709018

Group type: EXPERIMENTAL
Intervention: Albuterol aerosol (180 mcg, 2 puffs) followed by hourly albuterol aerosol for 5 hours (10 puffs = 900 mcg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Albuterol aerosol (180 mcg, 2 puffs) followed by hourly placebo for 5 hours
Number of subjects: 15
Study: 29027324

Group type: EXPERIMENTAL
Intervention: Higher circulating miR‐132 levels
Number of subjects: 953
Study: 27633766

Group type: EXPERIMENTAL
Intervention: Menthol e‐cigarettes
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Chocolate e‐cigarettes
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cherry e‐cigarettes
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tobacco e‐cigarettes
Number of subjects: 88
Study: 22738284

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Flexibility Training (FT)
Number of subjects: 60
Study: 23787163

Group type: EXPERIMENTAL
Intervention: Routine screening for Coxiella burnetii infection with immediate analysis of serum samples for IgM and IgG (phase I/II) and treatment during pregnancy
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Control group with sera frozen for analysis after delivery
Number of subjects: 1229
Study: 20442540

Group type: EXPERIMENTAL
Intervention: Aprotinin 20,000 KIU/kg after induction, 20,000 KIU/kg added to pump prime, 20,000 KIU/kg/hour infusion for three hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aprotinin 30,000 KIU/kg after induction, 30,000 KIU/kg added to pump prime, 30,000 KIU/kg/hour infusion for three hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aprotinin 40,000 KIU/kg after induction, 40,000 KIU/kg added to pump prime, 40,000 KIU/kg/hour infusion for three hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aprotinin 40,000 KIU/kg
Number of subjects: 24
Study: 18468815

Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg twice daily)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 15753526

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 20
Study: 12600228

Group type: EXPERIMENTAL
Intervention: Imatinib 400 or 600mg once daily
Number of subjects: 147
Study: 10580785

Group type: EXPERIMENTAL
Intervention: Waist action level 1 (waist circumference >=94 cm in men and >=80 cm in women)
Number of subjects: 32978

Group type: EXPERIMENTAL
Intervention: Waist action level 2 (waist circumference >=102 cm in men and >=88 cm in women, BMI >=30 kg/m2)
Number of subjects: 32978

Group type: COMPARATOR
Intervention: Cut-off points based on BMI (>=25 kg/m2) and waist-to-hip ratio (>=0.95 for men, >=0.80 for women)
Number of subjects: 32978
Study: 8732716

Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (60% energy from carbohydrate, 20% from fat)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-carbohydrate diet (40% energy from carbohydrate, 40% from fat)
Number of subjects: 18
Study: 1718369

Group type: EXPERIMENTAL
Intervention: Magnesium-rich diet
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 400
Study: 7063178

Group type: EXPERIMENTAL
Intervention: 4 cm3 of Xylocitin 2% with 0.00125% epinephrine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 4 cm3 of Xylocitin 2% with 0.002% epinephrine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 4 cm3 of Xylocitin 2% with 0.005% norepinephrine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 4 cm3 of Xylocitin 2% alone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal saline (placebo) or needle insertion only
Number of subjects: 44
Study: 31983019

Group type: EXPERIMENTAL
Intervention: Health Approach to Weight Management and Food in Eating Disorders (HAPIFED)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy-Enhanced (CBT-E)
Number of subjects: 98
Study: 29630438

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine co-administered with PHiD-CV and HRV
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 co-administered with PHiD-CV
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 co-administered with HRV
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 co-administered with aP antigens
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: PHiD-CV co-administered with RTS,S/AS01
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 co-administered with pediatric vaccines
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 and co-administered PHiD-CV, pertussis antigens and HRV
Number of subjects: 705

Group type: COMPARATOR
Intervention: HBV (Engerix B) vaccine
Number of subjects: 705
Study: 27105760

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 1462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1462
Study: 25502179

Group type: EXPERIMENTAL
Intervention: CERA administered every two weeks (Q2W)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CERA administered every four weeks (Q4W)
Number of subjects: 50
Study: 23301484

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment at Baihui (GV 20), pain point (Extra, right), Sanyangluo (TE 8, right), Zusanli (ST 36, right), and ear uterus point (right ear) after 50 mg dolantin injection
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group received 50 mg dolantin injection followed by oocyte retrieval after 30 min
Number of subjects: 134
Study: 20350923

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (group D)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 28
Study: 18609301

Group type: EXPERIMENTAL
Intervention: Chronic pain patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Controls (non-obese adults)
Number of subjects: 15
Study: 16321131

Group type: EXPERIMENTAL
Intervention: Newly designed thumb strap splint and abduction exercise regimen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Current clinical practice (short opponens splint and pinch exercise regimen)
Number of subjects: 40
Study: 14610125

Group type: EXPERIMENTAL
Intervention: High-resolution MRI in patients with ICD
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-resolution MRI in healthy controls
Number of subjects: 10
Study: 11190415

Group type: EXPERIMENTAL
Intervention: Fluconazole for antifungal prophylaxis in patients with prolonged neutropenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B at a daily dose of 0.6 to 1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid formulations of amphotericin B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amphotericin B for unstable candidiasis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole as an alternative
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New antifungal agents (new azoles)
Number of subjects: 0